PEG-MGF
A PEGylated version of MGF with extended half-life for systemic muscle growth and recovery effects.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is PEG-MGF?
PEG-MGF is a PEGylated form of Mechano Growth Factor where a polyethylene glycol molecule is attached to increase stability and extend the half-life from minutes to several hours. This allows systemic distribution and longer-lasting effects compared to standard MGF, though it may sacrifice some of the localized potency.
Why People Talk About It
Systemic muscle growth and recovery via satellite cell activation
PreliminaryExtended half-life compared to native MGF (hours vs minutes)
PreliminaryAnti-inflammatory and tissue-protective effects in muscle injury
PreliminaryPotential cardioprotective and neuroprotective properties
PreliminaryHow It Works
PEG-MGF is a longer-lasting version of the muscle repair signal MGF. The PEG coating protects it from breakdown, allowing it to circulate throughout the body and support muscle recovery systemically rather than just locally.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Not FDA-approved
- • Very limited human data
- • PEGylation may alter receptor-binding potency while extending duration
- • Long-term effects unknown
- • Listed as prohibited substance by WADA
What We Don't Know
Human safety and efficacy data are essentially nonexistent for PEG-MGF specifically. One study found MGF E-peptide alone had no apparent effect on myoblasts in isolation, raising questions about the mechanism. PEGylation effects on MGF bioactivity and receptor interactions need further characterization.
Published Research
16 studiesMechano-Growth Factor: an important cog or a loose screw in the repair machinery?
Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting.
The role of mechano growth factor in chondrocytes and cartilage defects: a concise review.
Age-related loss of muscle mass and strength.
Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages.
Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection.
Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury.
Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice.
A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia.
Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction.
Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction.
Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations.
Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells.
First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I.
Effects of resistance training on expression of IGF-I splice variants in younger and older men.
Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Related Peptides
MGF
EmergingA splice variant of IGF-1 produced in response to mechanical stress on muscles, promoting satellite cell activation and muscle repair.
IGF-1 LR3
EmergingA modified version of IGF-1 with extended half-life and reduced IGF binding protein affinity, used for muscle growth.
IGF-1 DES
EmergingA truncated form of IGF-1 missing the first 3 amino acids, with 10x greater potency and very short half-life for localized effects.
Quick Facts
- Class
- PEGylated Growth Factor
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Mar 2026
- Citations
- 16PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician